57.4 F
Pakistan
Friday, October 30, 2026
HomeHealthLilly reports retatrutide advantage over Ozempic in diabetes trial

Lilly reports retatrutide advantage over Ozempic in diabetes trial

Company topline results show larger blood-sugar and weight reductions, with more treatment discontinuation at the highest dose; the drug remains investigational. The post Lilly reports retatrutide advantage over Ozempic in diabetes trial appeared first on PakTribune.

Read full story on Paktribune

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -
Google search engine

Most Popular

Recent Comments